⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EBS News
Emergent Biosolutions, Inc.
Form 8-K
sec.gov
EBS
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
EBS
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
globenewswire.com
EBS
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
globenewswire.com
EBS
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
globenewswire.com
EBS
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
globenewswire.com
EBS
Vaccine Contract Manufacturing Market to Reach US$11,065.6 Million by 2036, as Immunisation Expansion and Rising Manufacturing Complexity Drive Outsourcing
globenewswire.com
EBS
Blood Plasma Derivatives Market to Reach USD 47.85 Billion by 2032 with a CAGR of 6.77%
globenewswire.com
EBS
GRFS
EBSCO Information Services Unveils Music Index Archive, Completing Its Trio of Music Research Resources
prnewswire.com
EBS
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
globenewswire.com
EBS